CoChat

The major determinant of exendin‐4/glucagon‐like peptide 1 differential affinity at the rat glucagon‐like peptide 1 receptor N‐terminal domain is a hydrogen bond from SER‐32 of exendin‐4

Open access
Mann, RJ, Nasr, NE, Sinfield, JK, Paci, E, Donnelly, D · 2010 · British Journal of Pharmacology
Cited by 35

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

BACKGROUND AND PURPOSE: Exendin‐4 (exenatide, Ex4) is a high‐affinity peptide agonist at the glucagon‐like peptide‐1 receptor (GLP‐1R), which has been approved as a treatment for type 2 diabetes. Part of the drug/hormone binding site was described in the crystal structures of both GLP‐1 and Ex4 bound to the isolated N‐terminal domain (NTD) of GLP‐1R. However, these structures do not account for the large difference in affinity between GLP‐1 and Ex4 at this isolated domain, or for the published role of the C‐terminal extension of Ex4. Our aim was to clarify the pharmacology of GLP‐1R in the context of these new structural data. EXPERIMENTAL APPROACH: The affinities of GLP‐1, Ex4 and various analogues were measured at human and rat GLP‐1R (hGLP‐1R and rGLP‐1R, respectively) and various receptor variants. Molecular dynamics coupled with in silico mutagenesis were used to model and interpret the data. KEY RESULTS: The membrane‐tethered NTD of hGLP‐1R displayed similar affinity for GLP‐1 and Ex4 in sharp contrast to previous studies using the soluble isolated domain. The selectivity at rGLP‐1R for Ex4(9–39) over Ex4(9–30) was due to Ser‐32 in the ligand. While this selectivity was not observed at hGLP‐1R, it was regained when Glu‐68 of hGLP‐1R was mutated to Asp. CONCLUSIONS AND IMPLICATIONS: GLP‐1 and Ex4 bind to the NTD of hGLP‐1R with similar affinity. A hydrogen bond between Ser32 of Ex4 and Asp‐68 of rGLP‐1R, which is not formed with Glu‐68 of hGLP‐1R, is responsible for the improved affinity of Ex4 at the rat receptor.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1476-5381.2010.00834.x

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 35

Metadata

Authors
Mann, R., Nasr, N., Sinfield, J., Paci, E., & Donnelly, D.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2010-05-03
Volume
160
Issue
8
Pages
1973-1984
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W2101524951
Cited by
35
References
5
FWCI
1.18
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The major determinant of exendin‐4/glucagon‐like peptide 1 differential affinity at the rat glucagon‐like peptide 1 receptor N‐terminal domain is a hydrogen bond from SER‐32 of exendin‐4. https://app.cochat.ai/papers/10.1111/j.1476-5381.2010.00834.x
The paper
Mann, R., Nasr, N., Sinfield, J., Paci, E., & Donnelly, D. (2010). The major determinant of exendin‐4/glucagon‐like peptide 1 differential affinity at the rat glucagon‐like peptide 1 receptor N‐terminal domain is a hydrogen bond from SER‐32 of exendin‐4. British Journal of Pharmacology. https://doi.org/10.1111/j.1476-5381.2010.00834.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.